



3.4.11 Translational Hepatology Group


Publications: 13 | **Q1:** 6

COMPOSITION

Francisco Javier García-Samaniego Rey.

Jefe de Sección en Hepatología. Hospital Universitario La Paz. Profesor Titular. Universidad Complutense De Madrid

- **Marina Cambor Murube.** Investigadora Predoctoral. Universidad Autónoma de Madrid
- **Antonio Madejón Seiz.** Investigador Postdoctoral. CIBERehd
- **Antonio Oliveira Martín.** Facultativo Especialista de Área en Hepatología. Hospital Universitario La Paz
- **Miriam Romero Portales.** Facultativo Especialista de Área en Gastroenterología. Hospital Universitario La Paz



STRATEGIC OBJECTIVES

- The research group conducted by Dr. García-Samaniego has extensive experience in the study of liver diseases, focusing its research activity, in both, clinical and basic aspects. In recent years the group has developed its activity preferentially in the study of viral hepatitis. The expertise areas of the research group are the study of infections caused by the hepatitis viruses [hepatitis viruses B (HBV), C (HCV) and delta (HDV)] and the chronic liver disease related to HBV, HCV and HDV at a time in which highly efficient antiviral systems against HBV, and especially against HCV has been developed.
- In addition to complete the research lines, the global strategy of the group will be focused in maintaining the high level of collaboration, both with CIBERehd research groups and with external groups, as well as to increase of the cooperation ways with private enterprise.

RESEARCH LINES

- Main research lines:
 1. Study of the epidemiological situation and optimization of the cascade of care for patients with infection by the hepatitis delta virus (HDV). Project in collaboration with the Hospital Clinic of Barcelona and Infanta Leonor of Madrid, and funded by the HDV DESCRIBE program sponsored by Gilead Scientific, S.A.
 2. Development of HCV micro-elimination strategies through the optimization and implementation of HCV detection and quantification systems at diagnostic points.
 3. Analysis of the role of epigenetic modifications induced by infection by hepatotropic viruses in the evolution of liver disease and the development of liver cancer, before and after antiviral treatment. Project performed in collaboration with the Department of Biochemistry of the Faculty of Medicine of the UAM and the Virology laboratory of the Molecular Biology Center "Severo Ochoa".
 4. Study of liver fibrosis progression factors in patients with metabolic hepatic steatosis.
- Alternative lines of work:
 1. Study of the role of the intestinal microbiota as a prognostic factor for adverse effects in biological cancer therapy. Project developed in collaboration with the Department of Biochemistry of the Faculty of Medicine of the UAM.
 2. Study of the influence of pre-existing liver disease on the evolution of COVID.



3.4 Large System Pathologies Area

RESEARCH ACTIVITY

Doctoral theses

- Gil García AI. Análisis genético y funcional del antígeno de superficie del virus de la hepatitis B aislado de pacientes antígeno e negativo en la zona gris de tratamiento.[dissertation]. *Madrid: UAM: 2023(25/05/2023). Director: García-Samaniego J, Madejón Seiz A.*

Publications

- Carrascosa JM, Vilarrasa E, Belinchón I, Herranz P, Crespo J, Guimerá F, Oliveira A. Common approach to metabolic-associated fatty liver disease in patients with psoriasis: consensus-based recommendations from a multidisciplinary group of experts. *Actas Dermosifiliogr.* 2023; 114(5): T392-T401. Article. IF: 3.8; Q1
- Crespo J, Cabezas J, Aguilera A, Albillos A, Buti M, Calleja JL, Montes JC, Martín MC, Diago M, Rodríguez CMF, Vázquez IF, Forn X, García F, García-Samaniego J, de Aguilar MHG, Jorquera F, Lazarus JV, Lens S, Martró E, García JMM, López MJ, Pineda JA, Rodríguez M, Romero-Gómez M, Antolín GS, Desfilis MAS, Turnes J. Opportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver. *Rev Esp Enferm Dig.* 2023; 115(3): 128-32. Article. IF: 2.7; Q2
- Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forn X, García F, García-Samaniego J, Hernández-Guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Pineda JA, Prieto M, Rodríguez-Frías F, Rodríguez M, Serra MA, Turnes J, Domínguez-Hernández R, Casado MA, Calleja JL. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. *Gastroent Hepat.* 2023; 46(2): 150-62. Article. IF: 2.2; Q3
- García-Crespo C, Francisco-Recuero I, Gallego I, Cambor-Murube M, Soria ME, López-López A, de Avila AI, Madejón A, García-Samaniego J, Domingo E, Sánchez-Pacheco A, Perales C. Hepatitis C virus fitness can influence the extent

of infection-mediated epigenetic modifications in the host cells. *Front Cell Infect Mi.* 2023; 13: 1057082. Article. IF: 4.6; Q2

- Mariño Z, Berenguer M, Peña-Quintana L, Oliveira A, Miralpeix A, Sastre I, Reyes-Domínguez A, Castillo P, García-Solà C, Bono A, Romero M, Pérez-Sádaba FJ, Aceituno S, Anguera A. Health-Related Quality of Life in Patients Living with Wilson Disease in Spain: A Cross-Sectional Observational Study. *J Clin Med.* 2023; 12(14): 4823. Article. IF: 3.0; Q1
- Martínez-Camprecios J, Riveiro-Barciela M, Muñoz-Gómez R, Londoño MC, Roget M, Serra MA, Escudero-García D, Purchades L, Rodríguez M, Losa-García JE, Gutiérrez ML, Carmona I, García-Samaniego J, Morano L, Martín-Granizo I, Montero-Alonso M, Prieto M, Delgado M, Ramos N, Azancot MA, Rodríguez-Frías F, Buti M. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy. *Gastroent Hepat.* 2023; 46(8): 594-602. Article. IF: 2.2; Q3
- Mateos-Muñoz B, Buti M, Vázquez IF, Conde MH, Bernal-Monterde V, Díaz-Fontenla F, Morillas RM, García-Buey L, Badía E, Miquel M, Amador-Navarrete A, Rodríguez-Tajes S, Ramos-Merino L, Madejón A, García-Retortillo M, Arenas JI, Cabezas J, Santiago JMG, Fernández-Rodríguez C, Cordero P, Diago M, Mancebo A, Pardo A, Rodríguez M, Hoyas E, Moreno JJ, Turnes J, Simón MA, Marcos-Fosch C, Calleja JL, Bañares R, Lens S, García-Samaniego J, Crespo J, Romero-Gómez M, Gea F, de Santiago ER, Moreno S, Albillos A. Tenofovir disoproxil fumarate reduces the severity of covid-19 in patients with chronic hepatitis b. *Digest Dis Sci.* 2023; 68(6): 2731-7. Article. IF: 2.5; Q2
- Mehta G, Riva A, Ballester MP, Uson E, Puja-das M, Carvalho-Gomes A, Sahuco I, Bono A, D'Amico F, Viganò R, Diago E, Lanseros BT, Inglese E, Vázquez DM, Sharma R, Tsou HLP, Harris N, Broekhoven A, Kikkert M, Morales

SPT, Myeni SK, Riveiro-Barciela M, Palom A, Zeni N, Brocca A, Cussigh A, Cmet S, Escudero-García D, Stocco M, Natola LA, Ieluzzi D, Paon V, Sangiovanni A, Farina E, di Benedetto C, Sánchez-Torrijos Y, Lucena-Varela A, Román E, Sánchez E, Sánchez-Aldehuelo R, López-Cardona J, Canas-Pérez I, Eastgate C, Jeyanesan D, Morocho AE, Di Cola S, Lapenna L, Zaccherini G, Bongiovanni D, Zanaga P, Sayaf K, Hossain S, Crespo J, Robles-Díaz M, Madejón A, Degroote H, Fernández J, Korenjak M, Verhelst X, García-Samaniego J, Andrade RJ, Iruzubietta P, Wright G, Caraceni P, Merli M, Patel VC, Gander A, Albillos A, Soriano G, Donato MF, Sacerdoti D, Toniutto P, Buti M, Duvoux C, Grossi PA, Berg T, Polak WG, Puoti M, Bosch-Comas A, Belli L, Burra P, Russo FP, Coenraad M, Calleja JL, Perricone G, Berenguer M, Claria J, Moreau R, Arroyo V, Angeli P, Sánchez C, Ampuero J, Piano S, Chokshi S, Jalan R. Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant. *Hepatol Commun.* 2023; 7(11): e0273. Article. IF: 5.6; Q1

- Oliveira A, Augustin S, Benlloch S, Ampuero J, Suárez-Pérez JA, Armesto S, Vilarrasa E, Belinchón-Romero I, Herranz P, Crespo J, Guimerá F, Gómez-Labrador L, Martín V, Carrascosa JM. The Essential Role of IL-17 as the pathogenetic link between psoriasis and metabolic-associated fatty liver disease. *Life (Basel).* 2023; 13(2): 419. Review. IF: 3.2; Q1
- Palom A, Almandoz E, Madejón A, Rando-Segura A, Pérez-Castano Y, Vico J, Gándara S, Battulga N, Gómez-I-Prat J, Riveiro-Barciela M, Ruiz-Tapiador JA, García-Samaniego J, Buti M. Communitystrategy for hepatitis b, c, and d screening and linkage to care in mongolians living in Spain. *Viruses-Basel.* 2023; 15(7): 1506. Article. IF: 3.8; Q2
- Razavi HA, Buti M, Terrault NA, Zeuzem S, Yurdaydin C, Tanaka J, Aghemo A, Akarca US, Al Masri NM, Alalwan AM, Aleman S, Alghamdi AS, Alghamdi S, Al-Hamoudi WK, Aljumah

AA, Altraif IH, Asselah T, Ben-Ari Z, Berg T, Biondi MJ, Blach S, Braga WSM, Brandao-Mello CE, Brunetto MR, Cabezas J, Cheinquer H, Chen PJ, Cheon ME, Chuang WL, Coffin CS, Coppola N, Craxi A, Crespo J, De Ledinghen V, Duberg AS, Etzion O, Ferraz MLG, Ferreira PRA, Forn X, Foster GR, Gaeta GB, Gamkrelidze I, García-Samaniego J, Gheorghe LS, Gholam PM, Gish RG, Glenn J, Hercun J, Hsu YC, Hu CC, Huang JF, Janjua N, Jia JD, Kåberg M, Kaita KDE, Kamal H, Kao JH, Kondili LA, Lagging M, Lázaro P, Lazarus JV, Lee MH, Lim YS, Marotta PJ, Navas MC, Naveira MCM, Orrego M, Osiowy C, Pan CQ, Pessoa MG, Raimondo G, Ramji A, Razavi-Shearer DM, Razavi-Shearer K, Ríos-Hincapié CY, Rodríguez M, Rosenberg WMC, Roulot DM, Ryder SD, Safadi R, Sanai FM, Santantonio TA, Sarrazin C, Shouval D, Tacke F, Tergast TL, Villalobos-Salcedo JM, Voeller AS, Yang H, Yu ML, Zuckerman E. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. *J Hepatol.* 2023; 79(2): 576-80. Article. IF: 26.8; D1

- Razavi-Shearer DM, Gamkrelidze I, Pan CQ, Jia JD, Berg T, Gray RT, Lim YS, Chen CJ, Ocamo P, Desalegn H, Abbas Z, Abdallah AR, Aghemo A, Ahmadbekova S, Ahn SH, Aho I, Akarca US, Al Masri NM, Alalwan AM, Alavian SM, Al-Busafi SA, Aleman S, Alfaleh FZ, Alghamdi AS, Al-Hamoudi WK, Aljumah AA, Al-Naamani K, Al-Rifai A, AlSerkal YM, Altraif IH, Amarsanaa J, Anderson M, Andersson M, Armstrong P, Asselah T, Athanasakis K, Baatarkhuu O, Ben-Ari Z, Bensalem A, Bessone F, Biondi MJ, Bizri ARN, Blach S, Braga WSM, Brandao-Mello CE, Brosgart CL, Brown KA, Jr RSB, Bruggmann P, Brunetto MR, Buti M, Cabezas J, Casanovas T, Chae CM, Chan HLY, Cheinquer H, Chen PJ, Cheng KJG, Cheon ME, Chien CH, Choudhuri G, Christensen PB, Chuang WL, Chulanov V, Garza LEC, Coffin CS, Contreras FA, Coppola N, Cornberg M, Cowie B, Cramp ME, Craxi A, Crespo J, Cui FQ, Cunningham CW, Dalgard



3.4 Large System Pathologies Area

O, De Knecht RJ, De Ledinghen V, Dore GJ, Drazilova S, Duberg AS, Egeonu S, Elbadri M, El-Kassas M, El-Sayed MH, Estes C, Etzion O, Farag E, Ferradini L, Ferreira PRA, Flisiak R, Fornis X, Frankova S, Fung J, Gane EJ, Garcia V, Garcia-Samaniego J, Gemilyan M, Genov J, Gheorghe LS, Gholam PM, Gish RG, Goleij P, Gottfredsson M, Grebely J, Gschwandler M, Guingane NA, Hajarizadeh B, Hamid SS, Hamoudi W, Harris AM, Hasan I, Hatzakis A, Hellard ME, Hercun J, Hernández J, Hockicková I, Hsu YC, Hu CC, Hsu P, Janicko M, Janjua N, Jarcuska P, Jaroszewicz J, Jelev D, Jeruma A, Johannessen A, Kåberg M, Kaita KDE, Kaliaskarova KS, Kao JH, Kelly-Hanku A, Khamis F, Khan AG, Kheir OO, Khoudri I, Kondili LA, Konysbekova A, Kristian P, Kwon JA, Lagging M, Laleman W, Lampertico P, Lavanchy D, Lázaro P, Lazarus J, Lee AU, Lee MH, Liakina V, Luksic B, Malekzadeh R, Malu AO, Marinho RT, Mendes-Correa MC, Merat S, Meshesha BR, Midgard H, Mohamed R, Mokhbat JE, Mooneyhan E, Moreno C, Mortgat L, Müllhaupt B, Musabaev E, Muyldermans G, Naveira MCM, Negro F, Nersesov A, Nguyen VTT, Ning Q, Njouom R, Ntagirabiri R, Nurmatov ZS, Oguche S, Omuemu CE, Ong JP, Opere-Sem OK, Örmeci N, Orrego M, Osiowy C, Papatheodoridis G, Peck-Radosavljevic M, Pessoa MG, Pham TND, Phillips RO, Pimenov N, Pincay-Rodríguez LDR, Plaseska-Karanfilska D, Pop C, Poustchi H, Prabdial-Sing NN, Qureshi H, Ramji A, Rautiainen H, Razavi-Shearer K, Remak WM, Ribeiro S, Ridruejo E, Ríos-Hincapié CY, Robalino MC, Roberts LR, Roberts SK, Rodríguez M, Roulot D, Rwegasha J, Ryder SD, Sadirova S, Saeed U, Safadi R, Sagalova O, Said SS, Salupere R, Sanai FM, Sánchez-Avila JF, Saraswat VA, Sargasyants N, Sarrazin C, Sarybayeva G, Schröter I, Seguin-Devaux C, Seto WK, Shah SR, Sharara A, Sheikh M, Shouval D, Sievert W, Simojoki K, Simonova MY, Sinn DH, Sonderup MW, Sonneveld MJ, Spearman

CW, Sperl J, Stauber RE, Stedman CAM, Sypsa V, Tacke F, Tan SS, Tanaka J, Tergast TL, Terrault NA, Thompson AJ, Thompson PJ, Tolman I, Tomasiewicz K, Tsang TY, Uzochukwu BSC, Van Welzen B, Vanwolleghem T, Vince A, Voeller AS, Waheed Y, Waked I, Wallace J, Wang C, Weis N, Wong GLH, Wong VWS, Wu JC, Yaghi CG, Yesmembetov K, Yip TCF, Yosry A, Yu ML, Yuen MF, Yurdaydin C, Zeuzem S, Zuckerman E, Razavi HA. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. *Lancet Gastroenterol Hepatol*. 2023; 8(10): 879-907. Article. IF: 30.9; D1

• **Romero-Gómez M, Aller R, Ampuero J, Rodríguez CF, Agustín S, Latorre R, Rivera-Esteban J, Urroz BM, García MLG, López SA, Albillos A, Hernández M, Graupera I, Benlloch S, Oliveira A, Crespo J, Calleja JL.** AEEH ?Consensus about detection and referral of hidden prevalent liver diseases? *Gastroent Hepat-Barc*. 2023; 46(3): 236-47. Article. IF: 2.2; Q3

Research projects

- **García-Samaniego Rey J.** Búsqueda activa de pacientes con hepatitis crónica viral (VHC YVHD) no diagnosticada, en población general, desde los Centros de salud de la Comunidad de Madrid. Gilead Sciences. 2022-2023. *Managment centre: FIBHULP*
- **García-Samaniego Rey J.** Epidemiological status of HDV infection in two big urban areas in Spain. Optimization of the cascade of care. Gilead Sciences (HDVDESCRIBE Program). 2022-2023. *Managment centre: CIBER*
- **García-Samaniego Rey J.** Estudio epidemiológico y molecular de la infección por VHD en una gran área urbana de España. Optimización de la cascada de atención (PI22/00849). ISCIII. 2023-2025. *Managment centre: ISCIII*

Cibers and Retics

- **CB06/04/0083 García-Samaniego Rey J.** Networked Biomedical Research Center for Hepatic and Digestive diseases. (CIBEREHD). ISCIII. (31/12/2023). FIBHULP

Clinical trials

- **Oliveira Martín A.** A randomized double-blind placebo-controlled phase 3 study to evaluate the effect of resmetrirom on liver-related outcomes in patients with well-compensated (child-pugh a) non-alcoholic steatohepatitis (nash) cirrhosis (maestro-nash outcomes).
Type/Phase: III
Sponsored by:
Signed date: 24/10/2023
- **García-Samaniego Rey J.** Estudio fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de la administración de bepirovirsén en pacientes con hepatitis b crónica y en tratamiento con análogos de nucleós(t)idos (bwell 2).
Type/Phase: III
Sponsored by: Glaxosmithkline Research And Development Limited
Signed date: 13/01/2023
- **García-Samaniego Rey J.** Estudio fase II, simple ciego, aleatorizado, controlado e internacional para evaluar la seguridad, reactogenicidad, eficacia y respuesta inmune tras el tratamiento secuencial con un oligonucleótido antisentido (aso) para la hepatitis b crónica (hbc) seguido de inmunoterapia dirigida contra la hepatitis b crónica (hbcit) en pacientes con hbc en tratamiento con análogos de nucleós(t)idos (an).
Type/Phase: II
Sponsored by: Glaxosmithkline S.A
Signed date: 09/01/2023
- **Oliveira Martín A.** Estudio de fase 2b, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de la efinopegdutida (mk-6024) en adultos con esteatohepatitis no alcohólica precirrótica.
Type/Phase: IIb
Sponsored by: Merck Sharp & Dohme LLC
Signed date: 06/06/2023
- **Oliveira Martín A.** Estudio fase IIA, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y farmacodinámica de azd4831 en pacientes con esteatohepatitis no alcohólica (ehna) no cirrótica con fibrosis.

Type/Phase: IIa

Sponsored by: Astrazeneca Farmaceutica Spain S.A
Signed date: 29/05/2023

- **García-Samaniego Rey J.** A registry study of treatment with bulevirtide in participants with chronic hepatitis d infection.

Type/Phase:

Sponsored by: Gilead Sciences Inc
Signed date: 13/09/2023

- **Oliveira Martín A.** Estudio clínico aleatorizado, doble ciego, controlado con placebo, multicéntrico, ininterumpido, adaptativo, de seguridad y búsqueda de dosis en fase iii de la transferencia génica mediada por vaa con ux701 para el tratamiento de la enfermedad de wilson.

Type/Phase: I

Sponsored by: Ultragenyx Pharmaceutical, Inc
Signed date: 08/10/2023

- **García-Samaniego Rey J.** Estudio fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de la administración de bepirovirsén en pacientes con hepatitis b crónica y en tratamiento con análogos de nucleós(t)idos (bwell 2).

Type/Phase: III

Sponsored by: Glaxosmithkline Research And Development Limited
Signed date: 25/08/2023

Patents and trademarks

- **Castán P, Gil-García AI, Madejón A, Sainz-Martínez E, Montoya JJ, Ouahid Younes, inventors; MIRONX BIOSENS S.L., assignee.** Bivalent reverse primers Application number (EPO): 20382336.4-1118. 2020 April 24.
- **Madejón A; inventor; Agile Life Sciences LTD, assignee.** Kit and methods Application number: GB202010372.A. 2020 July 6.